Evidence map›Paper›PMID 33507690›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2021

Cardiac, Hepatic and Renal Dysfunction and IL-18 Polymorphism in Breast, Colorectal, and Prostate Cancer Patients.

Govand Qader, Mukhlis Aali, Shukur W Smail, Kazhan Mahmood, Bestoon Hasan, Karwan M-Amen, Dlzar Bayz Rahman, Fikry A Qadir, Dara K Mohammad, Hastyar H Najmuldeen and 20 more

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 6 institutions in 2 countries.

Govand QaderDepartment of Biology, College of Science, Salahaddin University-Erbil, Kurdistan Region, Iraq.
Mukhlis AaliDepartment of Biology, College of Science, Salahaddin University-Erbil, Kurdistan Region, Iraq.
Shukur W SmailDepartment of Biology, College of Science, Salahaddin University-Erbil, Kurdistan Region, Iraq.
Kazhan MahmoodDepartment of Midwifery, College of Nursing, Hawler Medical University, Erbil, Kurdistan Region, Iraq.
Bestoon HasanDepartment of Cancer Registry, Cancer Control Unit, Erbil Directorate of Health, Erbil, Iraq.
Karwan M-AmenDepartment of Medical Analysis, Faculty of Science, Tishk International University, Erbil, Iraq.
Dlzar Bayz RahmanInternal Laboratory, Hawler Teaching Hospital, Erbil Directorate of Health, Erbil, Iraq.
Fikry A QadirDepartment of Biology, College of Science, Salahaddin University-Erbil, Kurdistan Region, Iraq.
Dara K MohammadCollege of Agricultural Engineering Sciences, Salahaddin University-Erbil, Erbil, Kurdistan Region, Iraq.
Hastyar H NajmuldeenDepartment of Biology, College of Science, University of Sulaimani, Kurdistan Region, Iraq.
Fryad Majeed RahmanDepartment of Biology, College of Science, University of Sulaimani, Kurdistan Region, Iraq.
Seepal Ibrahim AhmadEmergency Hospital, Duhok General Health Directorate, Duhok, Kurdistan Region, Iraq.
Nergz S SalihDepartment of Biology, College of Science, Salahaddin University-Erbil, Kurdistan Region, Iraq.
Zainab M KhdhrDepartment of Biology, College of Science, Salahaddin University-Erbil, Kurdistan Region, Iraq.
Bushra A MohammedDepartment of Biology, College of Science, Salahaddin University-Erbil, Kurdistan Region, Iraq.
Asuda M MajeedDepartment of Biology, College of Science, Salahaddin University-Erbil, Kurdistan Region, Iraq.
Xanda M HasanDepartment of Biology, College of Science, Salahaddin University-Erbil, Kurdistan Region, Iraq.
Bushra H KhidhirDepartment of Biology, College of Science, Salahaddin University-Erbil, Kurdistan Region, Iraq.
Eman S MuhammadDepartment of Biology, College of Science, Salahaddin University-Erbil, Kurdistan Region, Iraq.
Bahar A MuhamadsalihDepartment of Pathological Analysis, Faculty of Science, University of Knowledge, Erbil, Kurdistan Region, Iraq.
Simav K HasanDepartment of Pathological Analysis, Faculty of Science, University of Knowledge, Erbil, Kurdistan Region, Iraq.
Aram J HamadDepartment of Pathological Analysis, Faculty of Science, University of Knowledge, Erbil, Kurdistan Region, Iraq.
Zahra K EsmailDepartment of Pathological Analysis, Faculty of Science, University of Knowledge, Erbil, Kurdistan Region, Iraq.
Chra M IsmaelDepartment of Pathological Analysis, Faculty of Science, University of Knowledge, Erbil, Kurdistan Region, Iraq.
Shan M HusaenDepartment of Pathological Analysis, Faculty of Science, University of Knowledge, Erbil, Kurdistan Region, Iraq.
Chiavan A AbdullaDepartment of Pathological Analysis, Faculty of Science, University of Knowledge, Erbil, Kurdistan Region, Iraq.
Bashdar M HussenCollege of Pharmacy, Hawler Medical University, Kurdistan Region, Iraq.
Zjwan HouseinDepartment of Medical Laboratory Technology, Health Technical College, Erbil Polytechnic University, Erbil, Iraq.
Mudhir ShekhaDepartment of Biology, College of Science, Salahaddin University-Erbil, Kurdistan Region, Iraq.
Abbas SalihiDepartment of Biology, College of Science, Salahaddin University-Erbil, Kurdistan Region, Iraq.ORCID 0000-0002-2672-5785
Salahaddin University-Erbil · IQHawler Medical University · IQUniversity of Sulaimani · IQKarolinska Institutet · SESulaimani Polytechnic University · IQTishk International University · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe present study aimed to determine the alterations in the serum levels of tumor markers used to evaluate cardiac, renal and liver function, and detect the interleukin (IL)-18 rs1946518 polymorphism in breast (BC), colorectal (CRC) and prostate cancer (PCa) patients.

methodsBlood samples were collected from 65 female BC, 116 CRC, 79 PCa and 88 myocardial infarction (MI) patients, and 110 healthy individuals to determine the concentration of tumor and cardiac markers. Furthermore, the IL-18 rs1946518 polymorphism was assessed using amplification refractory mutation system (ARMS)-PCR.

resultsThe serum levels of the tumor markers cancer antigen 15-3 (CA 15-3), carbohydrate antigen 19-9 (CA 19-9), carcinoembryonic antigen (CEA) and total prostate-specific antigen (TPSA) were significantly increased in cancer patients compared with healthy controls. Furthermore, the activity of high-sensitivity cardiac troponin T (hs-cTnT) and creatine kinase‑myocardial band (CK-MB) was enhanced in MI patients, however, their activity was unchanged in cancer patients. The activity of alkaline phosphatase (ALP), and the serum concentration of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and urea were markedly elevated in CRC and PCa patients, respectively, compared with the control group. Although, no significant differences were observed in the -607 C/A polymorphism and allele frequency of IL-18 among BC, CRC patients and healthy individuals, the odds ratio (OR) was 1.75 for both C and A allele in BC patients. Therefore, the -607 C/A polymorphism could be considered as a risk factor for BC.

conclusionThe aforementioned results suggested that tumor markers could be considered as excellent biomarkers for the early detection of BC, CRC and PCa, whereas the concentration of liver enzymes could serve as an alternative indicator for the diagnosis of CRC and PCa. Additionally, the rs1946518 polymorphism in the IL-18 gene could be considered as a risk factor for the occurrence of BC, CRC and PCa.<br />.

Indexed as

Polymorphism, Single NucleotideBiomarkers, TumorBreast NeoplasmsCase-Control StudiesColorectal NeoplasmsFemaleFollow-Up StudiesHeart DiseasesHumansInterleukin-18Kidney DiseasesLiver DiseasesMalePrognosisProstatic NeoplasmsBiomarkers, TumorIL18 protein, humanInterleukin-18breast cancercolorectal cancerinterleukin-18 polymorphismProstate CancerTumor markers

Identifiers

PMID33507690
PMCPMC8184168
OpenAlexW3122770844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.